Incorporating Genomic Testing and Advanced Imaging For Prostate Cancer Into Your Practice Webcast (2024)

There are multiple genomic tests and advanced imaging modalities (MRI, prostate-specific membrane antigen PET, etc.) currently available for men to detect and risk-stratify prostate cancer. The outcomes of these tests may lead to different detection strategies (observation, immediate biopsy, etc.) and treatment decisions (active surveillance, surgery, radiation, adjuvant therapy, etc.). We will also discuss germline testing as inherited mutations have considerable implications for screening, treatment, genetic counseling and cascade testing of family members. The availability and marketing of genomic testing and advanced imaging have outpaced a reflective, evidence-based medicine approach to using these tests. Discussing the research studies that led to the approval of the various genomic tests, understanding the prognostic clinical end points they predict, reviewing current AUA and National Comprehensive Cancer Network Guidelines for prostate cancer genomic testing, examining available validation studies and utilizing case-based scenarios will provide participants with the knowledge to assess these tests and apply them to their clinical practice. The same methodology will be applied to advanced imaging modalities.


This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Identify the research that led to the approval of genomic cancer for prostate cancer and the implementation of advanced imaging for prostate cancer.
  2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation.
  3. State the National Comprehensive Cancer Network Guidelines for genomic testing and advanced imaging for prostate cancer.
  4. Discern the different prognostic end points provided by various genomic tests.
  5. Recognize candidates for, and implications of, germline testing for prostate cancer.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 


NameCompany NameRelationship TypeEnd Date
Cooperberg, Matthew RandalDendreonConsultant or AdvisorCurrent
AstellasConsultant or AdvisorCurrent
Astra ZenecaScientific Study or TrialCurrent
JanssenConsultant or AdvisorCurrent
Exact SciencesConsultant or Advisor10/10/2022
ExosomeDxConsultant or AdvisorCurrent
LynxDxConsultant or AdvisorCurrent
VeracyteConsultant or AdvisorCurrent
BayerConsultant or AdvisorCurrent
LantheusConsultant or AdvisorCurrent
PfizerConsultant or AdvisorCurrent
Lin, Daniel WeiClovis OncologyConsultant or Advisor06/30/2022
MagForce USAScientific Study or TrialCurrent
JanssenConsultant or AdvisorCurrent
LantheusConsultant or AdvisorCurrent
Pinto, Peter AnthonyPhilips/InVivo IncIntellectual PropertyCurrent
Wagner, Joseph RobertCovidienConsultant or AdvisorCurrent
Genomic HealthMeeting Participant or Lecturer12/30/2022



PDF iconEducation Council Disclosures


PDF iconCOI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2024
Expiration Date: May, 2025

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.